Group 1 - The core viewpoint of the article highlights the recent stock performance of 基石药业-B (02616), which saw an increase of nearly 5%, closing at 9.52 HKD with a trading volume of 78.05 million HKD [1] - Singapore's Government Investment Corporation (GIC Private Limited) increased its stake in 基石药业 by acquiring 80.4 million shares at an average price of 7.9 HKD per share, totaling approximately 635 million HKD, raising its ownership from 0.00% to 5.49% [1] - 基石药业 reported a significant decline in revenue for the first half of the year, amounting to 49.45 million RMB, a year-on-year decrease of 80.54%, while R&D expenses rose by 58.75% to 105 million RMB, resulting in a loss of 270 million RMB [1] Group 2 - The company announced a price adjustment for its drug 普拉替尼 in preparation for negotiations regarding the national medical insurance drug list, with expectations that inclusion in the list could lead to sales growth benefits starting in 2026, offsetting short-term revenue impacts [1] - In the first half of 2025, the company did not enter into any significant external licensing agreements, but it signed a major external licensing agreement with Gentili in July 2025, anticipating revenue from licensing fees in the second half of 2025 [1]

Group 1 - The core viewpoint of the article highlights the recent stock performance of 基石药业-B (02616), which saw an increase of nearly 5%, closing at 9.52 HKD with a trading volume of 78.05 million HKD [1] - Singapore's Government Investment Corporation (GIC Private Limited) increased its stake in 基石药业 by acquiring 80.4 million shares at an average price of 7.9 HKD per share, totaling approximately 635 million HKD, raising its ownership from 0.00% to 5.49% [1] - 基石药业 reported a significant decline in revenue for the first half of the year, amounting to 49.45 million RMB, a year-on-year decrease of 80.54%, while R&D expenses rose by 58.75% to 105 million RMB, resulting in a loss of 270 million RMB [1] Group 2 - The company announced plans to adjust the pricing of its drug 普拉替尼 in preparation for negotiations regarding the national medical insurance drug list, with expectations that inclusion in the list could lead to sales growth benefits starting in 2026 [1] - In the first half of 2025, the company did not enter into any significant external licensing agreements, but it signed a major external licensing agreement with Gentili in July 2025, anticipating revenue from licensing fees in the second half of 2025 [1]

Group 1 - The stock of Basilea Pharmaceutica (02616) increased by nearly 5%, reaching HKD 9.52 with a trading volume of HKD 78.05 million [1] - Singapore's Government Investment Corporation (GIC Private Limited) increased its stake in Basilea by acquiring 80.4 million shares at an average price of HKD 7.9, totaling approximately HKD 635 million, raising its ownership from 0.00% to 5.49% [1] - Basilea reported a mid-year revenue of RMB 49.45 million, a year-on-year decrease of 80.54%, while R&D expenses rose by 58.75% to RMB 105 million, resulting in a loss of RMB 270 million [1] Group 2 - The company is preparing for negotiations regarding the National Medical Insurance Drug List, adjusting the price of its drug, Pralsetinib [1] - If Pralsetinib is included in the National Medical Insurance List, the expected sales growth from 2026 onwards is anticipated to offset the short-term negative impact on revenue [1] - In the first half of 2025, the company did not enter into any significant external licensing agreements, but it signed a major external licensing agreement with Gentili in July 2025, expecting to receive licensing fee income in the second half of 2025 [1]

Market Overview - The Hong Kong stock market experienced a decline, with the Hang Seng Index falling by 0.24% to close at 25,104.61 points, and a total trading volume of HKD 239.49 billion [1] - The Hang Seng Tech Index was the worst performer, dropping 0.77% to 5,498.5 points [1] - Huatai Securities noted that the market is in a critical phase with a lack of trading themes and awaiting verification of significant domestic and overseas events, suggesting a window for position adjustment [1] Blue-Chip Stocks Performance - China Resources Power (00836) led the blue-chip decline, falling 5.9% to HKD 18.51, contributing a loss of 3.86 points to the Hang Seng Index [2] - The company reported a revenue of HKD 50.267 billion for the first half of 2025, a decrease of 1.67% year-on-year, and a profit attributable to shareholders of HKD 7.872 billion, down 15.92% [2] - Other notable blue-chip movements included China Biologic Products (01177) rising 3.49% and China Unicom (00762) increasing by 3.39% [2] Sector Highlights High-Speed Rail Infrastructure - Major technology stocks generally weakened, while high-speed rail infrastructure stocks performed well, with China CNR (01766) rising 5.85% and Times Electric (03898) increasing by 5.43% [3] - The National Railway Group announced a tender for 210 high-speed train sets, exceeding market expectations, indicating a positive outlook for the sector [3] Pharmaceutical Sector - The pharmaceutical sector saw most stocks rise, with Basilea Pharmaceutica (02616) increasing by 12.87% and Akeso (01167) rising by 10.04% [4] - The Chinese Premier emphasized the need for high-quality technological support and policy backing for the biopharmaceutical industry, aiming to enhance innovation and production of effective medicines [4] Stablecoin Concept Stocks - Stablecoin-related stocks were active, with ZhongAn Online (06060) rising 6.98% and Yao Cai Securities (01428) increasing by 5.75% [4] - Goldman Sachs reported a new expansion cycle for the stablecoin market, potentially reaching trillions of dollars, with payment applications being a key growth driver [6] Notable Stock Movements - Crystal International (02232) reached a new high, closing up 12.66% at HKD 6.85, reporting a revenue of USD 1.229 billion, a 12.4% increase year-on-year [7] - Hong Kong Robotics (00370) surged 12.86% after signing a significant order for 10,000 humanoid robots, marking a milestone in the industry [8] - Huazhu Group (01179) reported a total revenue of RMB 6.426 billion for Q2 2025, a 4.52% increase, with a net profit of RMB 1.544 billion, up 44.7% [9] - Great Wall Motors (02333) saw a rise of 6.45% following the launch of its new PHEV model, which received over 21,856 orders within 24 hours [10] - ZTE Corporation (00763) increased by 5.38%, with analysts highlighting its underestimated progress in AI and network business [11]

Group 1 - The stock of Basilea Pharmaceutica Ltd. (02616) increased by over 8%, reaching HKD 8.74 with a trading volume of HKD 11.72 million [1] - Singapore's Government Investment Corporation (GIC Private Limited) increased its stake in Basilea by acquiring 80.4 million shares at an average price of HKD 7.90 per share, totaling approximately HKD 635 million, resulting in a new holding of 5.49% [1] - Basilea reported a significant decline in revenue for the first half of the year, amounting to RMB 49.45 million, a decrease of 80.54% year-on-year, while R&D expenses rose by 58.75% to RMB 105 million, leading to a loss of RMB 270 million [1] Group 2 - Basilea's preclinical pipeline includes over nine potential candidates, focusing on FIC/BIC research across oncology, autoimmune, and inflammatory diseases [2] - The company has developed an innovative internal ADC technology platform that enhances the release of payloads selectively targeting tumors, supporting multiple ADC products in its pipeline [2] - The platform is expected to provide ongoing momentum for the company's future development [2]

Group 1 - The stock price of Basestone Pharmaceuticals-B (02616) increased by 8.17%, reaching HKD 8.74, with a trading volume of HKD 11.72 million [1] - Singapore's Government Investment Corporation (GIC Private Limited) increased its stake in Basestone Pharmaceuticals by acquiring 80.4 million shares at an average price of HKD 7.90 per share, totaling approximately HKD 635 million, resulting in a new holding of 5.49% [1] - Basestone Pharmaceuticals reported a mid-year revenue of RMB 49.45 million, a year-on-year decrease of 80.54%, while R&D expenses rose by 58.75% to RMB 105 million, leading to a net loss of RMB 270 million [1] Group 2 - Basestone Pharmaceuticals has a preclinical pipeline that includes over nine potential candidates, focusing on FIC/BIC research in oncology, autoimmune, and inflammatory diseases [2] - The company has developed an innovative internal ADC technology platform that enhances the release of payloads selectively targeting tumors, supporting multiple ADC products in its pipeline [2] - The platform is expected to provide ongoing momentum for the company's future development [2]

Group 1 - The Chinese government emphasizes the importance of the biopharmaceutical industry for public health and aims to enhance innovation and policy support to improve the quality and efficiency of drug development [1][2] - A recent meeting highlighted the need for original innovation and key technology breakthroughs, with a focus on integrating artificial intelligence into various stages of drug development and production [2] - The National Healthcare Security Administration has approved 534 drugs for the national basic medical insurance directory, indicating a growing support for innovative drugs [2][3] Group 2 - The biopharmaceutical sector in China is experiencing rapid growth, with over 100 licensing transactions worth $52.3 billion in 2024, marking a significant increase from $41.9 billion in 2023 [3] - The number of outbound licensing transactions has tripled compared to inbound transactions, showcasing China's increasing competitiveness in the global pharmaceutical market [3] - The market sentiment for innovative drugs has been positively impacted by recent supportive policies, with a focus on optimizing drug procurement and negotiation mechanisms [4][6] Group 3 - The oncology sector is highlighted as a key area for innovation, particularly in antibody-drug conjugates (ADCs) and immunotherapy, with significant opportunities for new product development [5] - The overall sentiment in the innovative drug sector remains optimistic, with expectations for continued policy support and improved commercial viability [6] - Companies like 基石药业-B, 和誉-B, 和铂医药, and 信达生物 are actively involved in innovative drug development and strategic partnerships, indicating a robust pipeline of new therapies [7][8]

| 股份代號: | 02616 | | --- | --- | | 上市法國名稱: | 基石藥業 - B | | 日期 (日 / 月 / 年): | 21/07/2025 - 21/08/202 | | 表格序號 | 大股東/董事/最高行政人員名 作出披露的買入 / 費出或涉及的 每股的平均價 | | | | 持有權益的股份數目 佔已發行的 有關事件的日 相關法 | | | --- | --- | --- | --- | --- | --- | --- | | | 股份數目 | 原因 | | | ( 請參閱上述 * 註 有投票權股 期 (日 / 月 / 份權益 | | | | | | | | 份自分比 年) | | | CS20250820E00015 | GIC Private Limited | 1001(L) | 80.400,000(L) | HKD 7.9000 | 80.400.000(L) | 5.49(L) 18/08/2025 | 格隆汇8月21日丨根据联交所最新权益披露资料显示，2025年8月18日，基石药业-B(02616.HK)获GIC Private Limited在场内以每股均价7 ...

香港联交所最新资料显示，8月18日，GIC Private Limited增持基石药业(02616)8040万股，平均每股作价 为7.90港元，总金额约为6.35亿港元。增持后最新持股数目为8040万股，持股比例为5.49%。 ...

智通财经APP获悉，香港联交所最新资料显示，8月18日，GIC Private Limited增持基石药业(02616)8040 万股，平均每股作价为7.90港元，总金额约为6.35亿港元。增持后最新持股数目为8040万股，持股比例 为5.49%。 ...